Search Result

Results for "

rituximab

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Apoptosis (1) CD19 (1) CD20 (5) Fc Receptor (FcR) (1) Radionuclide-Drug Conjugates (RDCs) (2) TNF Receptor (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (8) Inflammation/Immunology (6)

Inhibitors & Agonists

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9913

*Rituximab* Maximum Cited Publications 12 Publications Verification Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8	Radionuclide-Drug Conjugates (RDCs) CD20	Inflammation/Immunology Cancer
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

HY-P9913A

Rituximab (anti-CD20) Maximum Cited Publications 12 Publications Verification	CD20	Inflammation/Immunology Cancer
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .

HY-P99055

Urelumab	TNF Receptor	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99113

Inebilizumab 1 Publications Verification MEDI-551	ADC Antibody CD19	Inflammation/Immunology
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .

HY-P991225

BI-1206	Fc Receptor (FcR) CD20	Inflammation/Immunology Cancer
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .

HY-170899

TLR7 agonist 28	Toll-like Receptor (TLR)	Cancer
TLR7 agonist 28 (compound 3) is a potent TLR7 agonist. TLR7 agonist 28 can conjugat to antitumor monoclonal antibodies (mAbs) for cancer immunotherapy .

HY-P990649

PF-5212374 TRU-015	CD20	Inflammation/Immunology
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab (HY-P9913). PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases .

HY-P991902

NAV006	CD20	Cancer
NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a K_dof 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .

HY-178712

CT 32228	Apoptosis	Cancer
CT 32228 is an inhibitor of lysophosphatidic acid acyltransferase-β (LPAAT-β). CT 32228 inhibits tumor cell growth. CT 32228 exhibits IC₅₀ values of around 0.1-0.8 μM in various leukemia cell lines. CT 32228 induces caspase activation in DHL-4 and Ramos cells. CT 32228 induces apoptosis when combined with Rituximab (HY-P9913). CT 32228 results in a 50% xenograft growth delay in vivo. CT 32228 can be studied in research on acute leukemia .

HY-W1129940

p-SCN-Macropa	Radionuclide-Drug Conjugates (RDCs)	Cancer
p-SCN-Macropa is a bifunctional macrocyclic chelator featuring macrocyclic polyamine skeletons and thiocyanate (-SCN) reactive moieties. p-SCN-Macropa can conjugate with monoclonal antibodies including Nimotuzumab (HY-P9968), Rituximab (HY-P9913) and Trastuzumab (HY-P9907)-PEG6-DM1 for ²²⁵Ac radiolabeling to construct radioimmunoconjugates. p-SCN-Macropa is applicable for the research of colorectal cancer, HER2-positive breast cancer, TROP-2-positive cancers, and PSMA-positive cancers .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9913

*Rituximab* Maximum Cited Publications 12 Publications Verification Anti-Human CD20 type I, Chimeric Antibody; HSDB 7455; IDEC-C2B8	Radionuclide-Drug Conjugates (RDCs) CD20	Inflammation/Immunology Cancer
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

HY-P9913A

Rituximab (anti-CD20) Maximum Cited Publications 12 Publications Verification	CD20	Inflammation/Immunology Cancer
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .

HY-P99055

Urelumab	TNF Receptor	Inflammation/Immunology Cancer
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .

HY-P99113

Inebilizumab 1 Publications Verification MEDI-551	ADC Antibody CD19	Inflammation/Immunology
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .

HY-P991225

BI-1206	Fc Receptor (FcR) CD20	Inflammation/Immunology Cancer
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .

HY-P990649

PF-5212374 TRU-015	CD20	Inflammation/Immunology
PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab (HY-P9913). PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases .

HY-P991902

NAV006	CD20	Cancer
NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a K_dof 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.